Cardiology Unit, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
Department of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Policlinico Universitario Umberto I, Sapienza University of Rome, Rome, Italy.
Expert Rev Med Devices. 2023 Jul-Dec;20(8):673-679. doi: 10.1080/17434440.2023.2223968. Epub 2023 Jun 12.
Pacemaker-dependent (PM) patients with cardiac implantable electronic device (CIED) infection require implantation of a temporary-pacemaker (TP) and delayed endocardial reimplantation or implantation of an epicardial-pacing-system (EPI) before device extraction. Our aim was to compare the TP and EPI-strategy after CIED extraction through a meta-analysis.
We searched electronic databases up to 25 March 2022, for observational studies that reported clinical outcomes of PM-dependent patients implanted with TP or EPI-strategy after device extraction.
3 studies were included enrolling 339 patients (TP: 156 patients; EPI: 183 patients). TP compared to EPI showed reduction in the composite outcome of relevant complications (all-cause death, infections, need for revision or upgrading of the reimplanted CIED) (12.1% vs 28.9%; RR: 0.45; 95%CI: 0.25-0.81; = 0.008) and a trend in reduction of all-cause death (8.9% vs 14.2%; RR: 0.58; 95%CI: 0.33-1.05; = 0.07). Furthermore, TP-strategy proved to reduce need of upgrading (0% vs 12%; RR: 0.07; 95%CI: 0.01-0.52; = 0.009), reintervention on reimplanted CIED (1.9% vs 14.7%; RR: 0.15; 95%CI: 0.05-0.48; = 0.001) and significant increase in pacing threshold (0% vs 5.4%; RR: 0.17; 95%CI: 0.03-0.92; = 0.04), with a longer discharge time (MD: 9.60 days; 95%CI: 1.98-17.22; = 0.01).
TP-strategy led to a reduction of the composite outcome of all-cause death and complications, upgrading, reintervention on reimplanted CIED, and risk of increase in pacing threshold compared to EPI-strategy, with longer discharge time.
依赖起搏器(PM)的心脏植入式电子设备(CIED)感染患者需要在设备取出前植入临时起搏器(TP)和延迟心内膜再植入或植入心外膜起搏系统(EPI)。我们的目的是通过荟萃分析比较 CIED 取出后 TP 和 EPI 策略。
我们检索了截至 2022 年 3 月 25 日的电子数据库,以寻找报告 PM 依赖患者在设备取出后植入 TP 或 EPI 策略后临床结局的观察性研究。
纳入了 3 项研究,共纳入 339 例患者(TP:156 例;EPI:183 例)。与 EPI 相比,TP 组复合结局(全因死亡、感染、需要对再植入的 CIED 进行修订或升级)的发生率降低(12.1%比 28.9%;RR:0.45;95%CI:0.25-0.81; = 0.008),全因死亡的发生率呈降低趋势(8.9%比 14.2%;RR:0.58;95%CI:0.33-1.05; = 0.07)。此外,TP 策略还可降低升级的需求(0%比 12%;RR:0.07;95%CI:0.01-0.52; = 0.009)、再植入 CIED 的再介入(1.9%比 14.7%;RR:0.15;95%CI:0.05-0.48; = 0.001)和显著增加起搏阈值(0%比 5.4%;RR:0.17;95%CI:0.03-0.92; = 0.04),且出院时间更长(MD:9.60 天;95%CI:1.98-17.22; = 0.01)。
与 EPI 策略相比,TP 策略可降低全因死亡和并发症、升级、再植入 CIED 的再介入以及起搏阈值升高的风险,同时延长出院时间。